1v1 Institutional Counterparty Comparison
Roxe vs Sperax: Regulation, 6D Ratings & Safety Audit
Deterministic head-to-head benchmarking of Roxe (Roxe Inc.) and Sperax (Sperax Foundation Ltd) across primary regulatory filings, statutory Tier-1 authorisations, 6-Dimension compliance scores, execution software, and warning exposure.
Coverage: Financial institutions and registrants headquartered in the United States and Canada
- Roxe 6D Score
- 1.4
- Sperax 6D Score
- 1.3
- Regulated Licences
- 0 vs 0
- Warning Flags
- 0 vs 0
Roxe outranks Sperax by +0.1 pts in composite 6D scoring (1.4 vs 1.3)
On supervisory breadth, Roxe holds 0 active regulated licence(s) (0 Tier-1) out of 0 total filings and 0 warning count(s), whereas Sperax holds 0 active regulated licence(s) (0 Tier-1) out of 0 total filings and 0 warning count(s). Allocators should inspect the individual licence numbers and contracting legal entities below before onboarding.
6-Dimension Quantitative Scorecard Comparison
Head-to-head breakdown across all 6 proprietary evaluation dimensions (0.0–10.0 scale).
| Evaluation Dimension | Methodology Weight | Roxe | Sperax | Score Delta | Dimension Leader |
|---|---|---|---|---|---|
| Overall Composite 6D Score | 100% Composite | 1.4 | 1.3 | +0.1 | Roxe |
| Regulatory & Licensing Integrity (riskScore) | 30% Weight | 1.6 | 1.9 | +0.3 | Sperax |
| Execution & Software Infrastructure (industryScore) | 20% Weight | 1.0 | 1.0 | 0.0 | Statistical Tie |
| User Reputation & Complaint Telemetry (userScore) | 20% Weight | 0.0 | 0.0 | 0.0 | Statistical Tie |
| Institutional Brand Longevity (brandScore) | 15% Weight | 1.4 | 1.8 | +0.4 | Sperax |
| Global Market Influence & Footprint (influenceScore) | 15% Weight | 1.7 | 1.6 | +0.1 | Roxe |
Visual Architecture Benchmark: Roxe vs Sperax
Vector comparison exhibit generated from live supervisory snapshot metrics.
Regulatory Standing, Entity & Platform Comparison
Structural comparison of supervisory authorisations, domicile, execution terminals, and risk telemetry.
| Audit Attribute | Roxe | Sperax |
|---|---|---|
| Primary Legal Name | Roxe Inc. | Sperax Foundation Ltd |
| Source Risk Classification | Risk level not supplied | Risk level not supplied |
| Active Regulated / Total Filings | 0 regulated / 0 total (0 Tier-1) | 0 regulated / 0 total (0 Tier-1) |
| Recorded Certificate Numbers | None on file | None on file |
| Registered Domicile / Address | 1675 Broadway, New York, NY | - |
| Offered Asset Classes & Services | Multi-asset financial services | Multi-asset financial services |
| Execution Software & Terminals | Proprietary / Web Platform | Proprietary / Web Platform |
| Supported Client Languages | English | English |
| Warning / Exposure Count | 0 recorded warning(s) | 0 recorded warning(s) |
| Specialized Sub-Page Audits |
Related 1v1 Institutional Comparisons
Compare Roxe and Sperax against other regulated peers in our financial institutions and registrants headquartered in the united states and canada slice.
Frequently Asked Questions: Roxe vs Sperax
Deterministic counterparty comparison answers derived from supervisory records.
Which institution has stronger regulatory oversight: Roxe or Sperax?
Both Roxe and Sperax hold 0 regulated licence record(s) in our dataset. Specifically, Roxe maintains 0 total recorded filing(s) (none on file) with 0 warning flag(s), whereas Sperax maintains 0 recorded filing(s) (none on file) with 0 warning flag(s). Always confirm the specific subsidiary onboarding your account on the official regulator register.
How do the 6D quantitative compliance scores compare between Roxe and Sperax?
In Americas Firm Ledger's 6-Dimension scoring matrix (0.0–10.0 scale), Roxe records an Overall Score of 1.4 (Risk & Licensing: 1.6, Brand: 1.4, Market Influence: 1.7, User Reputation: 0.0, Execution & Software: 1.0), compared with Sperax at 1.3 Overall (Risk & Licensing: 1.9, Brand: 1.8, Market Influence: 1.6, User Reputation: 0.0, Execution & Software: 1.0).
How do Roxe and Sperax differ in trading platforms and asset classes?
Roxe lists general financial services with execution software [proprietary/web execution], while Sperax lists general financial services with execution software [proprietary/web execution]. Counterparties should verify FIX/API connectivity, server routing topology, and negative balance protection per entity.
Which counterparty carries lower regulatory warning and complaint exposure: Roxe or Sperax?
Roxe carries a "Risk level not supplied" classification with 0 warning/exposure count(s) and 0 user comment(s), while Sperax carries a "Risk level not supplied" classification with 0 warning/exposure count(s) and 0 user comment(s).
Structured against supervisory register snapshots and public regulatory filings. Verify your contracting legal entity and current authorisation status directly on the issuing regulator’s official register before transacting.